Gaviscon Tablets Extra Strength Cherry Flavor 100 Tablets ( Pack of 4)
$51.22
Price: $51.22
(as of May 06, 2024 14:20:22 UTC – Details)

Looking for reliable heartburn and acid reflux symptom relief? Look no further than doctor-recommended Gaviscon antacids. In addition to its fast-acting, acid-neutralizing properties, Gaviscon is the only antacid product that provides long-lasting relief.* It’s available in Extra Strength Tablet Antacid Original flavor, as well as Extra Strength Liquid Antacid Cool Mint flavor, Extra Strength Liquid Antacid Cherry flavor and Extra Strength Tablet Antacid Cherry flavor. With Gaviscon, you’ll always have an effective daily treatment for managing heartburn! Amongst national brands; *when used as directed. NDC Code(s): 0135-0096-26, 0135-0098-26, 0135-0430-03.
Is Discontinued By Manufacturer : No
Product Dimensions : 6 x 6 x 8 inches; 1.69 Pounds
Date First Available : October 23, 2013
Manufacturer : GlaxoSmithkline
ASIN : B004X8HEYU
Fast-Acting and Long-Lasting Relief: Gaviscon provides fast relief from symptoms of heartburn, acid indigestion, sour stomach, and upset stomach. It’s also known for providing long-lasting relief when used as directed.
Unique Acid-Neutralizing Properties: It is the only antacid product amongst national brands that offers both fast-acting and long-lasting relief.
Neutralizes Stomach Acid: Gaviscon works by quickly neutralizing stomach acid and helps to keep acid down for an extended period, providing lasting comfort and relief.
Available in Various Forms: Available in Extra Strength Tablet Antacid Original, Extra Strength Liquid Antacid in Cool Mint and Cherry flavors, and Extra Strength Tablet Antacid in Cherry flavor, providing options for individual preferences.
Recommended by Gastroenterologists: Gaviscon is recommended by gastroenterologists as an effective treatment for managing heartburn and acid reflux symptoms.
User Reviews
Be the first to review “Gaviscon Tablets Extra Strength Cherry Flavor 100 Tablets ( Pack of 4)”
$51.22
There are no reviews yet.